To Boost Or Not To Boost? Pfizer At Odds With US FDA

Pfizer Unphased By Apparent Pushback

US regulators indicate that authorizing booster shots is not a priority - but Pfizer still plans to seek an EUA in the fall.

US vaccination centre — Despite a rapid uptake from some US adults, so far only 54% have received at least one vaccine dose.

As many countries make plans for possible COVID-19 vaccine booster programs this fall, the US Food and Drug Administration and Centers for Disease Control have pushed back at the suggestion from Pfizer Inc. and BioNTech that the extra shots are necessary in the US – at least for now.

Companies with COVID-19 vaccines such as Pfizer/BioNTech and AstraZeneca have data that they say show a third dose of their vaccine produces greater efficacy, including against the newer Delta...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

29 May 2025

• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

29 May 2025

• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

29 May 2025

• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.